EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program

Grishma Hirode iD, Camelia Capraru, Aaron Vanderhoff iD, Andrew B Mendlowitz, Brett Wolfson-Stofko, Joel Karkada, David Smookler, Mediongo-Abasi Usoro, Steven M Friedman iD, Kathy Bates, Tony Mazzulli, Joshua V Juan und 5 weitere

Open Forum Infectious Diseases · 01.07.2026 · 13 (7)

DOI: 10.1093/ofid/ofag218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 01.07.2026. Verfasst von Grishma Hirode und 16 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Centre for Liver Disease/Viral Hepatitis Care Network (VIRCAN), University Health Network, Toronto, Ontario, Canada. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Viral Hepatitis Care Network, Gilead Sciences, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal hepatitis C virus (HCV) screening is required to prevent transmission and progression to advanced liver disease and to meet global elimination targets. While administrative health data can highlight trends in testing and treatment, additional information is required to understand barriers in the care cascade. We conducted a real-world analysis documenting the care cascade and the effectiveness of HCV antibody (Ab) screening modalities across different community and clinical settings.

Methods

This was a cross-sectional study of individuals who completed HCV Ab testing at participating centers in Ontario, Canada, between May 2010 and June 2023.

Results

Among 61 605 individuals tested, the prevalence of HCV Ab was 13.6% and highest among individuals aged 35–44 years (23.2%) and individuals tested at addiction clinics (41.0%). Among those with an HCV Ab–positive result, 79.7% ever completed RNA testing of whom 57.3% were RNA positive. Among those with an RNA-positive result, 65.0% attended a follow-up appointment. Among those who attended their appointment, 94.0% initiated treatment (61.1% of the RNA-positive), 77.4% of those who started had documented treatment completion (47.3% of the RNA-positive), and 59.6% of those who completed treatment had documented sustained virologic response 12 weeks after treatment (28.2% of the RNA-positive). The Ab testing modality was closely related to test setting, and primary care was the most effective at linkage to care.

Conclusions

While there was some attrition from HCV Ab positivity to RNA testing, treatment initiation was higher compared with administrative data. These results highlight the benefits of multiple testing modalities and matching the optimal Ab testing modality to the setting, with strong pathways for linkage to care.

Schlagwörter

Stichwörter der Autor:innen

barrierscascadehepatitis Cprevalencereal-world

Autor:innen und Institutionen

  • Toronto Centre for Liver Disease/Viral Hepatitis Care Network (VIRCAN), University Health Network, Toronto, Ontario, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Center for Drug Use and HIV/HCV Research (CDUHR), School of Global Public Health, NewYork University, New York, New York, USA.
  • Department of Emergency Medicine, University Health Network, Toronto, Ontario, Canada.
  • Emergency Department, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Grishma Hirode, Aaron Vanderhoff, Steven M Friedman, Mia J Biondi, Jordan J Feld

Förderung

  • Viral Hepatitis Care Network
  • Gilead Sciences
  • AbbVie
  • Merck Canada

Zitieren

APA

Hirode, G., Capraru, C., Vanderhoff, A., Mendlowitz, A. B., Wolfson-Stofko, B., Karkada, J., Smookler, D., Usoro, M. A., Friedman, S. M., Bates, K., Mazzulli, T., Juan, J. V., Shah, H., Hansen, B. E., Janssen, H. L. A., Biondi, M. J., & Feld, J. J. (2026). Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program. Open Forum Infectious Diseases, 13(7). https://doi.org/10.1093/ofid/ofag218

Vancouver

Hirode G, Capraru C, Vanderhoff A, Mendlowitz AB, Wolfson-Stofko B, Karkada J, et al. Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program. Open Forum Infectious Diseases. 2026;13(7). doi:10.1093/ofid/ofag218

BibTeX
@article{Hirode2026,
  author = {Hirode, Grishma and Capraru, Camelia and Vanderhoff, Aaron and Mendlowitz, Andrew B and Wolfson-Stofko, Brett and Karkada, Joel and Smookler, David and Usoro, Mediongo-Abasi and Friedman, Steven M and Bates, Kathy and Mazzulli, Tony and Juan, Joshua V and Shah, Hemant and Hansen, Bettina E and Janssen, Harry L A and Biondi, Mia J and Feld, Jordan J},
  title = {Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {7},
  doi = {10.1093/ofid/ofag218}
}
Kostenlos starten →